The nanoparticles predominantly accumulated in the liver, where they effectively reduced hepatic steatosis by modulating fat metabolism genes (such as by increasing CPT-1 and suppressing SREBP-1c), with a 100 mg/kg dose showing markedly stronger effects than an equivalent free berberine dose. This evidence concerns the gene CPT1A and fatty liver disease.